Arcutis reports Q4 product revenue ~$63M (+366% YoY); FY2024 ~$160M (+449% YoY)

Arcutis Biotherapeutics, Inc.

2024-FY EPS reported -$1.16 revenue$196,542,000

Preliminary Q4 2024 product revenue ~$63M, up ~366% vs Q4 2023 and ~41% vs Q3 2024.
Full-year 2024 product revenue ~$160M, up ~449% compared to 2023, driven by ZORYVE demand.
Cash and marketable securities ~$229M as of Dec 31, 2024; total liquidity ~$329M after $100M debt repayment and re-draw option.
Gross-to-net similar to prior quarter; robust unit growth across portfolio.
Company to report complete Q4/FY2024 results and host conference call on Feb 25, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.